Reports Q4 revenue $3M, consensus $9.42M.”Earlier this year, we announced the decision to focus all our resources on our late-stage notalgia paresthetica clinical program, which we believe puts us on the path to significant near-term value creation,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “We completed enrollment in KOURAGE 1 Part A, the dose-finding portion of our pivotal program, earlier than anticipated and now expect to report topline efficacy and safety results in the third quarter of 2024. With a sizeable patient population and no approved or effective therapies on the market, we are excited about the commercial potential for oral difelikefalin in NP. Importantly, our cash runway into 2026 gives us the resources necessary to reach all potential key value-inflection milestones in our NP clinical program.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARA:
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, March 04, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
- CARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today